PURPOSE: To determine the maximum tolerated dose in concurrent three-dimensional conformal radiotherapy (3D-CRT) with chemotherapy for unresectable Stage III @entity1149 ( @entity1149 ). @entity1 AND METHODS: Eligible @entity1 with unresectable Stage III @entity1149 , age >=  20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V(20))  <= 30% received three to four cycles of @entity900 (80 mg/m(2) Day 1) and @entity1206 (20 mg/m(2) Days 1 and 8) repeated every 4 weeks. The doses of 3D-CRT were 66 Gy, 72 Gy, and 78 Gy at dose levels 1 to 3, respectively. RESULTS: Of the 17, 16, and 24 @entity1 assessed for eligibility, 13 (76%), 12 (75%), and 6 (25%) were enrolled at dose levels 1 to 3, respectively. The main reasons for exclusion were V(20) >30% (n = 10) and @entity1445 to the esophagus (n = 8) and brachial plexus (n = 2). There were 26 @entity1 and 5 @entity1 , with a median age of 60 years (range, 41-75). The full planned dose of radiotherapy could be administered to all the @entity1 . Grade 3-4 @entity1398 and @entity1398 were noted in 24 (77%) and 5 (16%) of the 31 @entity1 , respectively. Grade 4 @entity281 , Grade 3 @entity2910 , and Grade 3 @entity358 were noted in 1 @entity1 , 2 @entity1 , and 1 @entity1 , respectively. The dose-limiting @entity137 was noted in 17% of the @entity1 at each dose level. The median survival and 3-year and 4-year survival rates were 41.9 months, 72.3%, and 49.2%, respectively. CONCLUSIONS: 72 Gy was the maximum dose that could be achieved in most @entity1 , given the predetermined normal tissue constraints.

Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using @entity900 and XXXX for unresectable stage III @entity1149 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'PATIENTS', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity'] @entity1445 :: ('MESH:D062787', 'Disease') :: ['overdose']
@entity1206 :: (MESH:C030852,Chemical) :: ['vinorelbine']
